In total, 48 patients presented with mutations in both JAK2V617F and TET2. As previously noted, although JAK2V617F first patients were predominantly PV patients of younger age, they have a higher risk of thrombotic events and present with abnormal blood counts compared with TET2 first patients [132]. This evidence concerns the gene TET2 and acquired polycythemia vera.